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Abstract
Objectives: This study was conducted to determine the incidence of early stasis in radioembolization
using resin yttrium-90 (Y-90) microspheres, to evaluate potential contributing factors, and to review initial
imaging outcomes.
Methods: Patients in whom early stasis occurred were compared with those in whom complete delivery
was achieved for tumour type and vascularity, tumour : normal liver ratio (T : N ratio) at technetium-99m-
macroaggregated albumin (Tc-99m-MAA) angiography, previous intra-arterial therapy, and infusion site
(left, right or whole liver). Tumour response was evaluated at 3 months and defined according to whether
a partial response and stable disease versus progressive disease were demonstrated.
Results: A total of 71 patients underwent 128 Y-90 infusions in which 26 (20.3%) stasis events occurred.
Hypervascular and hypovascular tumours had similar rates of stasis (17.4% versus 27.8%; P = NS). The
mean  standard deviation T : N ratio was 3.03  1.54 and 3.66  2.79 in patients with and without
stasis, respectively (P = NS). Stasis occurred in 14 of 81 (17.3%) and 12 of 47 (25.5%) infusions following
previous intra-arterial therapy and in therapy-naïve territories, respectively (P = NS). Early stasis occurred
in 15 of 41 (36.6%) left, 10 of 65 (15.4%) right and one of 22 (4.5%) whole liver infusions (P < 0.001). Rates
of partial response and stable disease were similar in the stasis (88.3%) and non-stasis (76.0%) groups
(P = NS).
Conclusions: Early stasis occurred in approximately 20% of infusions with similar incidences in hyper-
and hypovascular tumours. Whole-liver therapy reduced the incidence of stasis. Stasis did not appear to
affect initial imaging outcomes.
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Introduction
There are two yttrium-90 (Y-90) radioembolization devices com-
monly used in clinical practice. The TheraSphere® (MDS Nordion,
Inc., Ottawa, ON, Canada) is a glass microsphere which is US
Food and Drug Administration (FDA)-approved for the treat-
ment of hepatocellular carcinoma (HCC).1 SIR-Spheres® (Sirtex
Medical Ltd, North Sydney, NSW, Australia) are resin micro-
spheres which are FDA-approved for the treatment of metastatic
colorectal carcinoma with concomitant fludarabine.2 Although
these devices both emit beta radiation to induce tumour necrosis
following locoregional delivery, they are quite different: most
importantly, the glass microspheres contain a much greater
density of Y-90 per bead than do the resin microspheres. The net
result is that complete dose delivery is always accomplished with
glass microspheres without detectable angiographic evidence of
embolization.3 Given the lower density of Y-90 per bead afforded
by resin microspheres, full delivery is not always possible as the
target artery can develop stasis prior to the completion of
infusion.4
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Although stasis with resin microspheres is an anecdotally
known phenomenon, the exact incidence of this event and the
factors that contribute to it are not described in the literature.
Greater understanding of this event is valuable for multiple
reasons. Stasis prevents the delivery of the prescribed activity and
can result in non-target infusion with toxic dose administration to
extrahepatic tissues.5,6 As with other types of radiation therapy,
resin microspheres are ordered at a specified activity level with the
goal of administering a prescribed dose to the targeted tumour(s).
The brachytherapy effect of Y-90 microspheres allows the delivery
of a greater dose to the targeted liver tumour(s) than does external
beam radiation.7 However, early stasis may potentially lead to
early tumour progression secondary to suboptimal dose delivery.
The primary goals of this study were to define the incidence of
stasis in the study patient population and to evaluate potential
contributing factors. Secondary goals were to evaluate imaging
responses following treatment and to compare findings in the
groups in which complete dose delivery was and was not achieved.
Materials and methods
This study was approved by the institutional review board of
Thomas Jefferson University (Philadelphia, PA, USA). All patients
treated with resin Y-90 microspheres between January 2007 and
February 2010 were included. The criteria for treatment with Y-90
microspheres required that patients demonstrated: (i) confirmed
unresectable liver-dominant disease; (ii) an East Coast Oncology
Group performance status of 0–2; (iii) adequate liver function
(bilirubin of <1.8 mg/dL), haematologic parameters (granulocyte
and platelet counts of >1500/microliter and >50 000/microliter,
respectively, per mL blood) and renal function (creatinine of
<2.5 mg/dL), and (iv) the ability to undergo selective hepatic
angiography.
Criteria that excluded patients from treatment included: (i) a
life expectancy of <2 months; (ii) a side branch flow to the gas-
trointestinal tract that could not be avoided or embolized, and
(iii) an estimated lung dose of 30 Gy.
Yttrium-90 treatment
Baseline cross-sectional imaging, including computed tomogra-
phy (CT), magnetic resonance imaging (MRI) and/or positron
emission tomography (PET)-CT, was obtained based on the
primary tumour aetiology. All patients underwent mapping arte-
riography with side-branch embolization performed as previously
described.6,8 Following side-branch embolization, technetium-
99m-macroaggregated albumin (Tc-99m-MAA) was infused into
the target arteries to estimate the lung-shunt fraction and evaluate
for extrahepatic flow. If outcomes were satisfactory, the first treat-
ment was administered 10–21 days later. The dose prescribed was
based on body surface area (BSA) and calculated as:
A GBq BSA V Vtumour liver( ) = −( )+0 2.
where Vtumour and Vliver represent the volume of tumour and total
liver, respectively, and A represents radioactivity in GBq (gigabec-
querel). Body surface area in square metres was calculated as
0.20247 ¥ height (m)0.725 ¥ weight (kg)0.425.
Prescribed activity was calculated according to the patient’s
weight, height and tumour volume, and in line with the patient’s
history of previous therapy. In patients who had previously
received either systemic chemotherapy or intra-arterial liver-
directed therapy (chemo- or immunoembolization), the dose was
reduced by 25%.9,10 Patients were treated with lobar or whole-liver
infusion based on anatomy and tumour burden. If untreated liver
remained or if patients underwent whole-liver therapy in multiple
fractions, the second treatment was performed 4–6 weeks after the
initial infusion.
A standard practice for resin microsphere infusion was followed
by all operators. Infusions were performed by four board-certified
interventional radiologists with 5–17 years of experience (DJE,
JWM, CFG, DBB). The radioactive microsphere dose was pushed
through the proprietary delivery kit with small aliquots of sterile
water. After flushing the line clear, 2–3-mL aliquots of non-ionic
contrast [Ioversol 320 (Covidien, Inc., Hazelwood, MO, USA) or
Iodixanol 320 (GE Healthcare, Inc., Waukesha, WI, USA) in
patients with a glomerular filtration rate of <60 mL/min] were
injected and cleared with sterile water to ensure continued ante-
grade flow after each pulse of radioactive microsphere delivery.
Sterile water infusions were limited to the volume necessary to
infuse and clear the microspheres and contrast. When the delivery
vial was clear, the vial was emptied by priming the inlet line with
air (the ‘air shot’). For the purpose of this study, early stasis was
defined as an infusion in which the delivery of resin microspheres
was halted as a result of a lack of antegrade flow at angiography
during infusion. In all cases of early stasis, residual microspheres
remained in the delivery vial and the infusion was halted prior to
the air shot. Standard post-procedure measurements of the
residual dose within the vial were obtained in all patients using a
survey meter (portable ion chamber radiation monitor model
TBM-IC-AJI; Technical Associates, Canoga Park, CA, USA).
Factors contributing to stasis
Factors that might potentially contribute to early stasis were
identified and evaluated. Relationships were tested using chi-
squared, Fisher’s exact or t-tests. Factors included: (i) tumour
type; (ii) vascularity (hypo- versus hypervascular)11 based on
angiographic appearance; (iii) a low tumour : normal liver ratio
(T : N ratio) at scintigraphic imaging following Tc-99m-MAA
angiography; (iv) previous intra-arterial therapy, and (v) infusion
site (left, right or whole liver).
Potential effect of stasis on early outcomes
The delivery of an incomplete dose could potentially lead to the
failure of treatment and the early progression of disease. The
earliest time at which a measurable response to Y-90 therapy can be
obtained is at 3 months following treatment.12,13 As a primary goal
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of all intra-arterial therapies is to arrest disease progression, inci-
dences of intrahepatic progressive disease versus partial response
and stable disease at 3 months were evaluated in the stasis and
non-stasis groups using CT or MRI according to the RECIST
(response evaluation criteria in solid tumours) framework.
Results
Patient demographics are summarized in Table 1. Seventy-one
patients received 128 infusions during 79 cycles of therapy. Patient
ages ranged from 23 years to 91 years [median: 61 years; mean 
standard deviation (SD) 63  12 years]. Disease aetiology
included uveal melanoma (n = 43), colorectal carcinoma (n = 12),
HCC (n = 5), breast carcinoma (n = 3), neuroendocrine tumour
(n = 2), cholangiocarcinoma (n = 2), Merkel cell carcinoma (n =
1), prostate adenocarcinoma (n = 1), gastric carcinoma (n = 1) and
oesophageal carcinoma (n = 1). The patients underwent one to
four infusions (mean  SD: 1.7  0.6; median = 2). One, two,
three and four infusions were performed in 23, 41, five and two
patients, respectively. Prior to treatment with Y-90, 47 of 71
(66.2%) patients had undergone previous intra-arterial therapy
and another 20 of the 71 (28.2%) patients had exhausted first-
and, when applicable, second-line therapeutic regimens. The
mean  SD and median prescribed activity was 0.71  0.30 GBq
and 0.68 GBq (range: 0.2–1.6 GBq). The mean SD and median
delivered activity was 0.66  0.32 GBq and 0.61 GBq (range:
0.07–1.60 GBq).
Incidence of early stasis
Early stasis developed during 26 of 128 (20.3%) infusions. The
mean  SD and median percentages of prescribed activity deliv-
ered in this group were 64.5  19.3% and 70.0% (range: 24.4%–
87.1%). The relative values of prescribed and administered
activity in the stasis group are shown in Fig. 1. In the infusions
without early stasis (103/128, 79.7%), the mean SD and median
percentages of prescribed activity delivered were 99.5  5% and
100% (range: 83–108%). Thresholds of delivery in the early stasis
and non-stasis groups are outlined in Table 2. The upper range of
delivery in the early stasis group (86.9%) overlapped one patient
in the non-stasis group, in whom an infusion of 83.2% of the
prescribed activity was achieved despite the completion of the
procedure including the air shot.
Potential contributing factors
The stratification of stasis by tumour type is outlined in Table 3.
Outcomes by tumour vascularity in the entire cohort are pre-
sented in Table 4. In the entire cohort, hypovascularity did not
predict stasis during infusion (17.4% versus 27.8%; P = 0.22, d.f. =
1). At pre-procedure scintigraphic imaging, the mean SD T : N
ratio was 3.03 1.54 in patients with early stasis and 3.66 2.79
in those without early stasis (d.f.= 71, t = 1.55, P = NS). Eighty-one
of the 128 infusions (63.3%) were performed in a region that had
previously been treated with intra-arterial therapy. Early stasis
occurred in 14 of 81 (17.3%) infusions compared with 12 of 47
Table 1 Demographic characteristics of the study group
Characteristic n
Patients 71
Male 33
Female 38
Malignancy
Uveal melanoma 43
Colorectal carcinoma 12
Hepatocellular carcinoma 5
Breast carcinoma 3
Neuroendocrine tumour 2
Cholangiocarcinoma 2
Other 4
Previous intra-arterial therapy
Yes 81
No 47
Infusion site
Left 41
Right 65
Whole liver 22
1.2
Prescribed activity, GBq
Administered activity,
GBq1.0
0.8
0.6
0.4
0.2
0.0
1 3 5 7 9 11 13 15 17 19 21 23 25
Figure 1 Prescribed and administered activity in the 26 instances of
early stasis
Table 2 Delivery of prescribed yttrium-90 activity administered in
infusions in which early stasis did and did not occur
Delivery
achieved
Early stasis
infusions
(n = 26), n
No stasis
infusions
(n = 102), n
<50% 7 0
50–75% 13 0
76–90% 6 4
90–100% 0 99
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(25.6%) in territories that were naïve to intra-arterial treatment
(P = NS). Early stasis occurred in 15 of 41 (36.6%) left lobe
infusions, 10 of 65 (15.4%) right lobe infusions and one of 22
(4.5%) whole-liver infusions (P < 0.001).
Imaging outcomes
In the entire cohort at the initial follow-up imaging after one cycle
of therapy, partial response was present in 13 (16.5%), stable
disease was present in 50 (63.3%) and progressive disease was
identified in 16 (20.2%) patients. Imaging outcomes by group are
outlined in Table 5. In the early stasis group, progression of disease
was present following three of 25 (12.0%) cycles of therapy. Partial
response or stable disease was present following 22 of 25 (88.0%)
cycles of therapy. In the non-progressive disease subgroup, three
of 22 cycles (13.6%) achieved a partial response and 19 of 22
(86.4%) achieved stable disease. In the non-stasis group, progres-
sion of disease was present after 13 of 54 (24.1%) treatment cycles.
Partial response or stable disease was present following 41 of 54
(75.9%) cycles of treatment. Ten of 41 (24.4%) patients in this
subgroup demonstrated a partial response and 31 of 41 (75.6%)
achieved stable disease. The early stasis group demonstrated a rate
of disease control (88.3%) similar to that in patients who received
the entire vial of spheres (76.0%) (P = NS).
Discussion
There are significant differences between the Y-90 agents currently
available. Each has limitations as currently configured. Resin
microspheres range in size from 20 mm to 60 mm and contain
50 Bq/particle, whereas glass microspheres measure 20–30 mm in
size and contain 2500 Bq/particle.14 As a result, 3-GBq vials of
resin and glass microspheres contain up to 80 ¥ 106 and 1.2 ¥ 106
spheres, respectively. These differences contribute to the limita-
tions of each device. Glass microspheres are non-embolic and
virtually no vascular changes are identified following infusion.3 As
a result, issues with early stasis are non-existent and it is easier to
deliver an equivalent or greater amount of activity using glass
rather than resin microspheres. Outcomes with glass micro-
spheres have been most impressive in patients with limited
tumour burdens.15,16 Bangash et al. studied the use of glass micro-
spheres in patients with metastatic breast cancer. Survival rates in
patients with, respectively, <25% and >25% tumour burdens were
9.4 months and 2.0 months.15 Patients with colorectal cancer
treated with glass microspheres showed a similar discrepancy in
survival rates as patients with <25% and >25% replacement sur-
vived 18.7 months and 5.2 months, respectively.16 In a pilot study
exploring the potential treatment of greater disease burdens,
Lewandowski et al. treated 50 patients with glass microspheres
that were allowed to decay for 2–3 days longer while maintaining
the same target dose of 120 Gy.14 This approach led to the infusion
of a larger number of microspheres to achieve the same adminis-
tration. This study demonstrated reasonable safety and efficacy,
and obtained improved results in larger tumours.14
The weakness of glass microspheres should theoretically imply
the strength of resin microspheres. Coverage of the entire arterial
supply of the targeted tumour(s) is less challenging, even for
larger masses. The principal limitation of resin Y-90 microspheres
is that early stasis in the infused artery can occur prior to complete
dose delivery. Murthy et al. described stasis that prematurely ter-
minated six of 19 infusions of resin microspheres.4 Outcomes in
the present study indicated that approximately 20% of infusions
are halted by angiographic stasis prior to complete dose delivery.
The maximum delivered activity in any single case in which early
stasis occurred was 86.9%; in half the patients, <75% of the
intended activity was administered prior to stasis. By comparison,
96.0% of completed infusions resulted in the administration of
>90% of the prescribed activity. Given the strengths and weak-
nesses of the devices currently available, it is likely that the optimal
Table 3 Incidence of stasis by tumour type
Pathology Patients,
n
Infusions,
n
Stasis
events,
n
Incidence
of stasis
Uveal melanoma 43 78 12 15.4%
Colorectal carcinoma 12 19 7 36.8%
Hepatocellular
carcinoma
5 7 1 14.3%
Breast 3 7 1 14.3%
Carcinoid 2 5 3 60.0%
Cholangiocarcinoma 2 4 0 0%
Merkel cell lymphoma 1 2 2 100%
Prostate 1 2 0 0%
Gastric 1 2 0 0%
Oesophageal 1 2 0 0%
Table 4 Outcomes by tumour vascularity
Vascularity Patients,
n
Infusions,
n
Stasis
events,
n
Incidence
of stasisa
Hypovascular 21 36 10 27.8%
Hypervascular 50 92 16 17.4%
aThe difference in the incidence of stasis between hypovascular and
hypervascular tumours was not statistically significant.
Table 5 Initial imaging findings in the early stasis and complete deliv-
ery groupsa
Response Early stasis
infusions, n
No stasis
infusions, n
Progressive disease 3/25 13/54
Stable disease/partial response 22/25 41/54
Partial response 3/25 10/54
Stable disease 19/25 31/54
aThe rate of intrahepatic progression was similar between patient groups
(P = 0.17).
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radioembolic in terms of Y-90 loading density and embolic poten-
tial would be a hybrid of the glass and resin devices in present use.
When stasis events were analysed according to tumour type, no
clear patterns were identified. Although a comparison of out-
comes in patients with, respectively, classically hypervascular
tumours (uveal melanoma) and classically hypovascular tumours
(colorectal cancer) yielded a significant difference in incidences of
stasis, it is important to note that stasis still developed in 15.4% of
uveal melanoma patients and was also seen in other hypervascular
pathologies, such as HCC and carcinoid tumours. Further, when
the entire cohort was assessed according to vascularity, no signifi-
cant difference in the incidence of stasis by the presence or absence
of hypervascularity emerged. A relative measure of tumour vas-
cularity is the T : N ratio. This measure has been used to estimate
ability to deliver resin Y-90 microspheres.10 The present authors
hypothesized that the T : N ratio would be lower in patients reach-
ing early stasis as hypervascular tumours with a higher T : N ratio
would absorb more microspheres, leaving the lobar arteries
patent. However, the T : N ratio was similar in patients reaching
early stasis and those who achieved complete infusion.
A number of patients in the present series had previously
undergone intra-arterial therapy with chemo- or immunoemboli-
zation, using gelfoam as the embolic agent.17 This metric was
chosen for evaluation as recanalization rates following intra-
arterial therapies can vary, ranging from 56% to 83% depending
on the technique used.18,19 Despite multiple treatments in targeted
territories prior to Y-90 therapy, no significant differences
emerged in the facility with which spheres could be delivered in
comparison with that in treatment-naïve arteries.
The final potential factor investigated in the present study was
infusion location. The incidence of early stasis was significantly
lower in whole-liver infusions compared with left or right lobe
infusions. Early stasis occurred in only one whole-liver infusion.
Sixteen of the 22 whole-liver infusions performed in the present
patient group were fractionated so that patients underwent infu-
sion of the entire liver twice with half the prescribed dose given at
each visit. The method used to prescribe activity utilizes the
patient’s BSA and the ratio of tumour to liver volume to deter-
mine the prescription. Although lobar infusions are almost uni-
versally targeted for completion in a single visit, the fractionating
of whole-liver treatments in the majority of patients undergoing
this technique results in the halving of infusion activity, which is
likely to have contributed to the lower incidence of early stasis in
whole-liver treatments compared with lobar infusions.
Understanding of the ideal dosimetry for radioembolization
with resin microspheres continues to evolve. The present study
utilized the BSA method to calculate prescribed activity, which is
the recommended approach.9,10 Dose reduction is a topic of
potential debate, although it is widely used in practice. Kennedy
et al. described the alteration of prescribed activity using the BSA
method in 491 of 500 (98.2%) infusions.10 Concern for liver tol-
erance secondary to previous therapy and a low T : N ratio were
included as two primary reasons for adjustment. Although the
standardization of dose reduction is suboptimal, this technique is
used in clinical practice to calculate an appropriate activity pre-
scription with resin microspheres in heavily pretreated patients, as
the majority of the present population were. Patients presenting
with normal liver function following previous therapy can be at
risk for toxicity from therapy. Hepatic steatosis and fibrosis fol-
lowing systemic therapy are commonly present after one treat-
ment regimen in the setting of normal liver function tests.20,21
Piana et al. described a significantly increased risk for hepatic
toxicity in patients undergoing resin microsphere administration
who had previously undergone intra-arterial therapy.22 Given the
palliative nature of treatment in this salvage group, dose reduction
was reasonable in these patients.
In the current series, the possibility that incomplete dose deliv-
ery would predispose patients to immediate treatment failure and
the progression of disease was of concern, although the present
authors acknowledge that some patients progress despite the clini-
cally successful delivery of therapy. Incidences of progressive
disease in both groups were statistically similar, although an
overall lower percentage of patients in the stasis group were found
to have progressed at 3 months. A time-point at 3 months from
treatment was selected for this measure because outcomes of Y-90
therapy take longer to evolve compared with those of chemoem-
bolization and the 3-month time-point is typically the earliest at
which responses can be discerned.12,13 The lack of early progres-
sion, if it proves durable, may suggest that the ischaemia associ-
ated with arterial stasis assists in achieving tumour necrosis even
when dose delivery is not maximized.
The present study has limitations. The retrospective construct
resulted in a varied patient group with outcomes tracked to 3
months. However, given the mix of diagnoses in the patient group,
it was considered that initial failures should be targeted in this
initial effort. The present series represents a salvage population.
Other reports in similar mixed patient groups treated with salvage
radioembolization have reported mean overall survival of 8–12
months.23,24 Based on the radiographic findings and survival in
other studies, imaging at 3 months should be predictive of the
future direction of these patients.12,13 The present study did not
quantify all chemotherapy regimens administered to patients or
the date of the last chemotherapy, although this may have con-
tributed to the occurrence of stasis. Additionally, the potential for
spasm resulting from the infusion of sterile water and/or the
microspheres is unknown. Although stasis is an accepted endpoint
for the discontinuance of infusion, maximal benefit may perhaps
be obtained at an earlier stage of occlusion, such as by pruning of
the peripheral arteries. The relative contributions of ischaemia
and brachytherapy with reference to resin microspheres are
unknown. Stasis as an endpoint remains controversial, even in the
more established chemoembolization literature.25
In summary, early stasis occurred in 20.3% of infusions in the
present series during resin microsphere administration. Early
stasis was identified in both hyper- and hypovascular tumours and
the presence of prominent tumour vascularity did not eliminate
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the potential for early stasis. However, stasis did not increase the
risk for progression at initial follow-up, which implies that
patients who develop stasis during the first of two planned treat-
ment sessions can potentially derive benefit from the second pro-
cedure. The performance of whole-liver infusions significantly
decreased the risk for early stasis and may be an optimal strategy
in heavily pretreated patients.
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